Wepredic

Executive Summary

Wepredic is a French biotechnology group founded in 2011, offering integrated solutions for evaluating the safety, fate, and bioavailability of drugs, cosmetics, and industrial chemicals. Operating through three complementary brands, the company provides biological assay systems, safety assessment services, and specialized chemical probes. Headquartered in Rennes, France, Wepredic serves clients in the pharmaceutical, cosmetic, and chemical sectors, helping them meet regulatory requirements and optimize product development. The company's expertise in predictive toxicology and ADME (absorption, distribution, metabolism, excretion) positions it as a key player in the early-stage screening and risk assessment market. Despite its niche focus, Wepredic's services are essential for reducing costly late-stage failures and ensuring compliance with evolving global safety standards. The company is privately held and has not disclosed funding or valuation details, but its continued operation since 2011 indicates sustained demand for its solutions.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Top-10 Pharmaceutical Company65% success
• Q4 2026Launch of a Next-Generation High-Throughput Screening Platform70% success
• Q1 2027Adoption of New EU Chemical Safety Regulations Driving Demand80% success